Sophie Le Coeur

Dr. Sophie Le Coeur

Institut National d'Etudes Démographiques
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LXLuyi Xu
Luyi Xu
KMKerim M Munir
Kerim M Munir
CKCheeraya Kanabkaew
Cheeraya Kanabkaew
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
Existing studies have suggested decreased adherence and rebound in mortality in perinatally HIV-infected adolescents receiving antiretroviral therapy (ART) as compared to adults and young children. We used both quantitative and qualitative approaches to identify factors influencing adherence among perinatally infected adolescents in Thailand. We analyzed data from 568 pairs of perinatally infected adolescents (aged 12–19) and their primary caregivers in the Teens Living With Antiretrovirals (TEEWA) study, a cross-sectional survey conducted in 2010–2012. We also conducted 12 in-depth interviews in 2014 with infected adolescents or their primary caregivers to elicit experiences of living with long-term ART. From the quantitative analysis, a total of 275 (48.4%) adolescents had evidence of suboptimal adherence based on this composite outcome: adolescents self-reported missing doses in the past 7 days, caregiver rating of overall adherence as suboptimal, or latest HIV-RNA viral load ≥1000 copies/ml. In multivariate logistic regression analysis, younger age, having grandparents or extended family members as the primary caregiver, caregiver-assessed poor intellectual ability, having a boy/girlfriend, frequent online chatting, self-reported unhappiness and easiness in asking doctors questions were significantly associated with suboptimal adherence. From the in-depth interviews, tensed relationships with caregivers, forgetfulness due to busy schedules, and fear of disclosing HIV status to others, especially boy/girlfriends, were important contributors to suboptimal adherence. Social and emotional support and counseling from peer group was consistently reported as a strong adherence-promoting factor. Our findings highlight unique barriers of ART adherence among the perinatally infected adolescents. Future interventions should be targeted at helping adolescents to improve interpersonal relationships and build adaptive skills in recognizing and addressing challenging situations related to ART taking.

1 September 2009 in Social Science & Medicine
Verified
Journal Article
Closed access
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
ICIntira J. Collins
Intira J. Collins
JPJulie Pannetier
Julie Pannetier
ÉLÉva Lelièvre
Éva Lelièvre

1 January 2005 in AIDS
Verified
Journal Article
Closed access
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
MKMyriam Khlat
Myriam Khlat
GHGaston Halembokaka
Gaston Halembokaka
CAChristine Augereau-Vacher
Christine Augereau-Vacher
GBGeorges Batala-M’pOndo
Georges Batala-M’pOndo
CRCarine Ronsmans
Carine Ronsmans
The extent to which HIV affects pregnancy-related mortality in countries with high HIV/AIDS and maternal mortality is poorly understood. The objectives of this study were to investigate the mortality of women of reproductive age by both HIV and pregnancy status, and quantify the excess mortality attributable to HIV during pregnancy in Pointe Noire, Congo. Prospective mortuary investigation of all deaths in women aged 15–44 years, during 112 consecutive days. Mortality rates by HIV and pregnancy were computed. During the study period, 378 corpses were examined, blood was tested for HIV and pregnancy, relatives were interviewed and hospital files were reviewed. Denominators were obtained from a census with women-years assigned to pregnancy and/or HIV based on levels of fertility and HIV prevalence in the city. The mortality rate was 32 times higher [95% confidence interval (CI), 25–39] among HIV-positive than among HIV-negative women. The relative increase in mortality associated with HIV was much higher in non-pregnant [rate ratio (RR), 41; 95% CI, 32–52] than in pregnant women (RR, 4; 95% CI, 2–9). Among HIV-positive women, pregnancy appeared to confer a survival benefit. These findings have important implications for the interpretation of trends in maternal mortality in the context of HIV. The apparent survival benefit of pregnant HIV-positive women is largely due to their low fertility in the latest stage of the disease. As the HIV epidemic matures and more women become severely ill, any potential adverse effects associated with HIV and pregnancy may be increasingly offset by selection effects, and maternal mortality may not increase further.

28 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FVFlorian Verrier
Florian Verrier
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
TDTristan Delory
Tristan Delory
Women living with HIV (WLHIV) are prone to harbor several high-risk human papillomavirus (HR-HPV) genotypes and to develop cervical cancerous lesions. Data on HPV prevalence in these women are needed to inform immunization programs, especially in Asia where few data are available. We conducted a systematic review and meta-analysis to estimate the prevalence of HPV and HR-HPV cervical infection in WLHIV in Asia and identify possible sources of heterogeneity for HR-HPV carriage. Pooled prevalence and its 95% confidence interval (95CI) were estimated using the inverse-variance weighting method. Linear regression weighted on study size was used to identify sources of heterogeneity. Among 7834 WLHIV (40 studies), the prevalence of HPV infection was 42.6% (95CI, 38.2% to 47.1%), and 34.6% (95CI, 30.3% to 39.1%) harbored HR-HPV genotypes, with significant heterogeneity across countries. In India, Thailand, and China, HPV-16 was the most frequent genotype (10.3%), followed by HPV-52 (5.4%), HPV-58 (5.0%), HPV-18 (4.1%), and HPV-33 (3.3%). In these women, most of whom were receiving antiretroviral therapy, we did not identify determinants of heterogeneity for HR-HPV infection. Our results underline the need for immunization programs based on nonavalent or new generation vaccines to prevent cervical cancer in WLHIV in Asia.

28 November 2015 in AIDS
Verified
Journal Article
Closed access
MLMarc Lallemant
Marc Lallemant
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
WSWasna Sirirungsi
Wasna Sirirungsi
TCTim R. Cressey
Tim R. Cressey
NNNicole Ngo-Giang-Huong
Nicole Ngo-Giang-Huong
SKSuporn Koetsawang
Suporn Koetsawang
Objectives: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective of this trial was to compare two maternal sdNVP-sparing regimens with standard zidovudine (ZDV)/sdNVP prophylaxis. Design: PHPT-5 was a randomized, partially double-blind placebo-controlled, noninferiority trial in Thailand (NCT00409591). Study participants were women with CD4+ of at least 250 cells/μl and their infants. Methods: All women received ZDV from 28 weeks’ gestation and their newborn infants for one week. Women were also randomized to receive NVP-NVP (reference): maternal intrapartum sdNVP with a 7-day ‘tail’ of ZDV along with lamivudine, and infant NVP (one dose immediately, another 48 h later); infant-only NVP: maternal placebos for sdNVP and the ‘tail’, with infant NVP; LPV/r: maternal LPV/r starting at 28 weeks. Infants were formula-fed. HIV-diagnosis was determined by DNA-PCR. Results: Four-hundred and thirty-five women were randomized between January 2009 and September 2010. Accrual was terminated prematurely following a change in Thai guidelines recommending antiretroviral combination therapy for all pregnant women. Data on 405 mothers and 407 live-born children were analyzed. Baseline characteristics were similar between arms. Intent-to-treat transmission rates were 3.8% (95% confidence interval: 1.2–8.6) in NVP-NVP, 1.6% (0.2–5.6) in infant-only NVP, and 1.4% (0.4–5.1) in LPV/r arms. As-treated rates were 2.2% (0.5–6.4), 3.2% (0.9–7.9), and 1.5% (0.2–5.2), respectively. Factors independently associated with transmission were prophylaxis duration less than 8 weeks (adjusted odds ratio 15.5; 3.6–66.1) and viral load at baseline at least 4 log10copies/ml (adjusted odds ratio 10.9; 1.3–91.5). Regimens appeared well tolerated. Conclusion: Transmission rates in all arms were low but noninferiority was not proven. Antiretroviral prophylaxis for at least 8 weeks before delivery is necessary to minimize transmission risk.

14 October 2005 in AIDS
Verified
Journal Article
Closed access
Sophie Le CoeurSophie Le Coeur
Sophie Le Coeur
GHGaston Halembokaka
Gaston Halembokaka
MKMyriam Khlat
Myriam Khlat
NBNicolas Brouard
Nicolas Brouard
FPFrancke Purhuence
Francke Purhuence
MLMarc Lallemant
Marc Lallemant
To measure the impact of AIDS on adult mortality by systematically investigating all deaths during 3 months, in the city of Pointe-Noire where the HIV epidemic emerged 20 years ago and levelled-off around 5% among adults. Exhaustive morgue-based study, in a city where by law all bodies should be registered at the morgue before they can be legally buried. From 30 June to 19 October 2001, a clinical examination of all bodies registered at the morgue was performed by a physician, and blood samples were systematically drawn for HIV testing. Relatives were interviewed on circumstances of death. Additional information was gathered from hospital files for cases previously hospitalized. Age- and sex-specific mortality rates were calculated using the population at risk derived from the 2001 census. Overall, 1309 adult deaths were investigated and 96.5% of the bodies registered at the morgue were tested for HIV. Forty-five percent of the deaths (570) were due to AIDS. The HIV prevalence was higher in female than in male deaths (57.1 versus 44.8%; P < 0.001). The AIDS-mortality rate among adults was 6.3 per thousand for women and 4.9 per thousand for men. Among 1000 young adults aged 15 years, 442 girls and 482 boys will not reach age 60 years (45q15). Without AIDS these would have been 216 and 307, respectively. Our study provides a direct measure of the impact of AIDS on mortality relative to other causes. In the most productive age group, 25–44 years, mortality is tripled by AIDS.